CeriBell, Inc. CBLL
27.80 USD +0.32 (+1.16%)
At closeNov 12, 2026, 4:03 AM EST
27.93 +0.13 +0.45%
Pre-market · Nov 12, 4:03 AM ET
27.58 Day range 28.27
12.36 52-week range 28.89
- YTD
- +26.77%
- 1 year
- +122.04%
News
benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $33 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $26 to $33.
benzinga.com CeriBell Q3 2026 Earnings Call Transcript CeriBell (NASDAQ:CBLL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com CeriBell Raises FY2026 Sales Guidance from $114.000M-$117.000M to $115.000M-$117.000M vs $115.537M Est CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $114.000 million-$117.000 million to $115.000 million-$117.000 million vs $115.537 million estimate.
benzinga.com CeriBell Q3 EPS $(0.55) Misses $(0.51) Estimate, Sales $29.341M Beat $29.164M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 48.65 percent decrease over losses of $(0.37)…
benzinga.com TD Cowen Maintains Buy on CeriBell, Raises Price Target to $33 TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $33.
benzinga.com Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC…- benzinga.com BTIG Maintains Buy on CeriBell, Raises Price Target to $30 BTIG analyst Marie Thibault maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $28 to $30.
- benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $25 to $26.
benzinga.com CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.000 million-$117.000 million vs $113.979 million estimate.- benzinga.com CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Based Neurology Portal: Epileptiform Abnormality Detection And Artifact Reduction CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
- benzinga.com CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor System CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
- benzinga.com CeriBell Highlights Publication Of New Research Paper, 'Point-Of-Care EEG Artificial Intelligence Measure Of Seizure Burden Associates With Clinical Outcome At Discharge' CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that a…
- benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Lowers Price Target to $25 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $28 to $25.
- benzinga.com CeriBell Raises FY2026 Sales Guidance from $111.000M-$115.000M to $112.000M-$116.000M vs $113.138M Est CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $111.000 million-$115.000 million to $112.000 million-$116.000 million vs $113.138 million estimate.
benzinga.com CeriBell Q1 EPS $(0.52) Misses $(0.39) Estimate, Sales $26.494M Beat $26.088M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.39) by 33.33 percent. This is a 44.44 percent decrease over losses of $(0.36)…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com CeriBell Q4 EPS $(0.36) Beats $(0.41) Estimate, Sales $24.784M Beat $23.942M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.41) by 12.62 percent. This is a 10 percent increase over losses of $(0.40) per…
- benzinga.com Earnings Scheduled For February 24, 2026
benzinga.com CeriBell's Earnings: A Preview 
benzinga.com Forecasting The Future: 5 Analyst Projections For CeriBell - benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $30 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $30.
benzinga.com Academy Sports and Outdoors, Tronox, STAAR Surgical And Other Big Stocks Moving Higher On Tuesday - benzinga.com CeriBell's Clarity Algorithm Gets FDA's Clearance To Detect Electrographic Seizures In Newborns Pre-Term, Older CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Earnings Scheduled For August 5, 2025 - benzinga.com Earnings Scheduled For May 8, 2025
benzinga.com Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday - benzinga.com Earnings Scheduled For February 25, 2025
benzinga.com Earnings Scheduled For November 12, 2024